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Introduction
The	 discussion	 concerning	 Calorie	 Restriction	 (CR)	 and	 low	
carbohydrate	 diet	 (LCD)	 has	 been	 continued	 for	 years.	 Several	
significant	 reports	 indicating	 predominance	 of	 LCD	 were	
published	[1-6].	Consequently,	LCD	has	been	estimated	to	have	
clinical	efficacy	in	nutritional	therapy	for	the	patients	with	type	2	
diabetes	mellitus	(T2DM)	and	metabolic	syndrome.	Authors	and	
colleagues have lots of experience of LCD for T2DM, and reported 
clinical	 studies	 [7-10].	Our	 recent	 study	 includes	blood	glucose	
variability	 in	 diabetic	 patients,	 using	Morbus	 (M)	 value,	 which	
is one of the index of blood sugar level and mean amplitude of 
glycemic	excursions	(MAGE)	[11-14].	
On	the	other	hand,	lipid	metabolism	in	metabolic	syndrome	has	
been	also	in	discussion,	and	recent	studies	include	remnant-like	
particle	cholesterol	(RLP-C)	[15-18].	Combined	these	aspects,	we	
investigated	blood	glucose	variability	for	the	M-value	in	diabetic	
patients,	and	lipid	metabolism	including	RLP-C	in	this	study.
Materials and Methods
The	 subjects	 were	 121	 patients	 with	 Type	 2	 diabetes	mellitus	
(T2DM),	which	were	52	males	and	69	females,	with	age	groups	
Abstract
Carbohydrate	and	lipid	metabolism	were	studied.	Subjects	were	121	patients	with	
type	2	diabetes	mellitus	(T2DM),	and	provided	Calorie	restriction	(CR)	on	day	1,2	
and	Low	Carbohydrate	Diet	(LCD)	from	3	to	14	days.	Basal	biomarkers,	daily	glucose	
profile	on	day	2,	4,	and	lipids	including	remnant-like	particle	cholesterol	(RLP-C)	
were	measured,	 subjects	were	 classified	 into	 4	 groups	 due	 to	 average	 glucose	
with	mean	HbA1c	6.3%,	6.9%,	7.9%,	9.2%,	respectively.	Average	glucose	from	day	
2	to	4	in	each	group	was	significantly	decreased.	M	value	considerably	decreased	
in	group	2,	3,	4,	indicating	useful	M	value.	Correlations	were	investigated	among	
glucose,	HbA1c,	urinary	C-Peptide	and	M	value.	
As	for	 lipids,	Triglyceride	from	day	2	to	14	decreased	considerably.	RLP-C	levels	
showed	significant	correlation	with	Triglyceride,	LDL-C,	atherogenic	index	(T-C	–
HDL	/	HDL)	and	TG/HDL	value.	These	 results	would	 suggest	 that	RLP-C	may	be	
involved in the development of arteriosclerosis of T2DM, and may have the role 
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In current study, our results would become the fundamental data for the further 
development	of	 LCD	 therapy	 in	 various	 counties	 and	districts,	 and	 suggest	 the	
research	direction	 for	patients	with	T2DM	from	the	combined	point	of	glucose	
and lipid metabolism in the future. 
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ranging between	28-84	years	old,	60.8	±	11.0	(mean	±	SD)	years	
old	 in	 average,	 63	 years	 old	 in	 the	 median	 value.	 They	 were	
admitted	for	14-15	days,	and	received	endocrine	and	metabolic	
evaluation	with	lipid	analysis.	
Methods	 included	 a	 controlled	 diet	 for	 the	 patients.	On	 day	 1	
and	 2,	 Calorie	 Restriction	 (CR)	 diet	 was	 provided	 which	 had	
60%	carbohydrates,	25%	lipids	and	15%	protein	with	1400	kcal/
day.	 From	day	3	 to	14	days,	 Low	Carbohydrate	Diet	 (LCD)	was	
provided,	 which	 had	 12%	 carbohydrates,	 64%	 lipids	 and	 24%	
protein	 with	 1400	 kcal/day.	 This	 has	 been	 called	 super-LCD	
formula	in	our	nutritional	investigation	for	LCD	[7,9,10,19].	
The	 examination	 protocol	 was	 as	 follows:	 1)	 basal	 biomarkers	
and	 daily	 profile	 of	 blood	 glucose	 on	 day	 2,	 2)	 daily	 profile	 of	
blood	glucose	on	day	4,	3)	several	biomarkers	such	as	triglyceride	
and uric acid on day 14.
Analysis method and M value
A	 daily	 profile	 of	 blood	 glucose	 was	measured	 7	 times	 a	 day,	
and data were calculated for average glucose level and Morbus 
(M) value.	According	to	the	average	glucose	level,	subjects	were
classified	into	4	groups,	namely,	group	1,2,3,4.
Morbus	(M)	value	has	been	proposed	for	analyzing	blood	glucose	
variability.	 It	 is	a	logarithmic	transformation	of	the	deviation	of	
blood glucose from an arbitrary assigned “ideal” glucose value, 
with	an	expression	of	both	the	mean	glucose	value	and	the	effect	
of	glucose	swings	[11-14,20].
The	 formula	 of	 M	 value	 is	 as	 follows:	 M=MBS	 +	 MW,	 where	
MW=(maximum	blood	glucose	−	minimum	glucose)/20;	MBS=the	
mean	 of	 MBSBS;	 MBSBS=individual	 M-value	 for	 each	 blood	
glucose	value	 calculated	as	 (absolute	 value	of	 [10	×	 log	 (blood	
glucose	value/120)])	[3].
For	 the	 interpretation	of	M	value,	 the	 standard	 range	 is	 <180,	
borderline	 is	 180-320	 and	 abnormal	 is	 >320.	 There	 were	
discussions	concerning	how	many	times	of	 sampling	per	day	 is	
necessary.	It	was	reported	that	multiple	sampling	and	a	7-point	
glycemic trial per day would have yielded similar	results	[14,21].	
Statistical analyses
In	current	study,	data	was	represented	as	the	mean	±	standard	
deviation.	 For	 statistical	 analyses,	 correlation	 coefficients	
(Pearson)	were	 calculated	 using	 the	 JMP	 (Version	 8)	 statistical	
analysis	software	(JMP	Japan	Division	of	SAS	Institute	Japan	Ltd.,	
Minato-ku,	Tokyo,	Japan)	and	Microsoft	Excel	analytical	tool.
Intergroup comparisons were made using the Wilcoxon rank sum 
test	or	the	Bonferroni	multiple	comparison	(Lambert	method).	A	
significance	level	of	less	than	5%	obtained	using	a	two-tailed	test	
was	considered	to	be	statistically	significant.	
Ethical considerations
Current study was conducted in compliance with the ethical 
principles	of	the	Declaration	of	Helsinki	and	Japan’s	Act	on	the	
Protection	 of	 Personal	 Information	 along	 with	 the	 Ministerial	
Ordinance	on	Good	Clinical	Practice	(GCP)	for	Drug	(Ordinance	of	
Ministry	of	Health	and	Welfare	No.	28	of	March	27,	1997).
No	ethical	committee	meeting	was	held.	Informed	consent	was	
obtained	 from	 the	 subjects	 concerning	 this	 questionnaire.	 The	
study was registered	with	UMIN	#R000031211.
Results
Fundamental data 
Summarized data of 121 subjects were shown in Table 1. They 
were categorized for 4 groups due to the average glucose level. 
The	 mean	 HbA1c	 in	 each	 group	 was	 6.3%,	 6.9%,	 7.9%,	 9.2%,	
respectively.	 Blood	 glucose	 level	 on	 day	 4	 was	 significantly	
decreased compared with those on day 2 in each group. 
Triglyceride	level	on	day	14	was	significantly	decreased	compared	
with those on day 2 in each group.
Correlation for HbA1c, glucose and M value
There were	 significant	 correlation	 between	 average	 glucose	
and HbA1c (Figure 1),	 and	 for	 the	 urinary	 C-peptide	 excretion	
between day 2 and 4 (Figure 2).
Average	glucose	on	day	2	and	4	revealed	significant	correlation	
(p<0.01),	 and	 M	 value	 on	 day	 2	 and	 4	 revealed	 significant	
correlation	(p<0.01)	(Figure 3).
Average	glucose	and	M	value	on	day	2	and	4	showed	significant	
correlation	(p<0.01)	(Figure 4).
Compared	with	both	figures,	average	glucose	and	M	value	on	day	
4 decreased apparently. The change of M value in each group 
from day 2 to day 4 were shown in (Figure 5).
Analyses among lipid biomarkers
The change of TG levels from day 2 to day 14 were shown in 
Figure 6. In response to LCD for 12 days, Triglyceride level was 
significantly	decreased	(p<0.05).	The	regression	curve	(y=0.3738x	
+ 44.072)	reveled	the	degree	of	decreased	TG.
RLP-C	 levels	showed	significant	correlation	with	Triglyceride	on	
day	2	(p<0.01)	and	LDL-C	on	day	2(p<0.05)	(Figure 7).
RLP-C	 showed	 significant	 correlation	 with	 atherogenic	 index	
(T-C–HDL/HDL)	(p<0.05),	and	TG/HDL	value	(p<0.01)	(Figure 8).
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Categorization
group Group 1 Group 2 Group 3 Group 4
Subjects
number 30 30 30 31
sex	(male/female) 13/17 13/17 10/20 16/15
age	(y.o.) 60	(54-65) 64	(51-70) 65	(55-72) 64	(56-68)
average	glucose	(mg/dL) 123	(115-128) 161	(141-168) 198	(184-212) 259	(248-294)
Glucose (basal)
HbA1c	(%) 6.3	(5.9-7.1) 6.9	(6.3-7.4) 72	(7.4-9.1) 22	(8.5-10.2)
Fasting	Glucose	(mg/dL) 111	(102-135) 132	(118-141) 170	(151-205) 210	(186-235)
IRI	(µU/mL) 7.4	(6.0-12) 7.5	(3.9-10.4) 5.3	(3.6-10.1) 5.4	(3.1-7.8)
HOMA-R 2.4	(1.3-4.0) 2.4	(1.2-3.8) 2.1	(1.3-4.3) 23	(1.5-4.2)
HOMA-β 60	(30-85) 41	(24-58) 21	(11-40) 11	(7.7-17)
Glucose (M value related)
average	glucose	on	day	2	(mg/dL)	 123	(115-128) 161	(150-179) 198	(184-212) 259	(248-294)
average	glucose	on	day	4	(mg/dL) 101	(97-113) 125	(112-137) 152	(143-164) 185	(166-205)
M value on day 2 8.9	(5.7	-	21.7) 42.9	(33.1	-52.0) 120	(96.8	-	151) 325	(269	-	509)
M value on day 4 8.5	(4.2	-	14.8) 5.4	(3.2	-	9.5) 14.8	(7.6	-	28.1) 60.1	(32.8	-105)
Glucose (CPR excretion in urine) 
urinary	CPR	on	day	2	(mg/day) 67.3	(27.3-105) 56.5	(36.5-86.8) 59.4	(38.5-66.2) 74.0	(50.5-89.7)
urinary	CPR	on	day	4	(mg/day) 56.0	(34.1-73.0) 40.8	(25.5-52.1) 43.3	(33.8-83.4) 64.0	(51.0-73.0)
Lipid Metabolism
Triglyceride	on	day	2		(mg/dL) 113	(71-143) 94	(67.5-157) 96	(73.5-125) 114	(70-175)
Triglyceride	on	day	14		(mg/dL) 93	(59-111) 88	(61.5-99) 69	(56-89) 88	(71-113)
HDL-C	on	day	2		(mg/dL) 57	(49-72) 57	(48-68) 65	(58.3-76) 63	(53-89)
HDL-C	on	day	14		(mg/dL) 47.5	(42-68) 50	(44-62) 58	(52-74)	 59	(46-70)
LDL-C	on	day	2		(mg/dL) 109	(97-137) 132	(102-1551) 126	(104-158) 145	(103-171)
LDL-C	on	day	14		(mg/dL) 120	(110-141) 138	(115-175) 137	(113-160) 155	(114-180)
RLP-C	on	day	2		(mg/dL) 4.4	(3.3-6.7) 4.1	(3.0-7.5) 4.8	(4.0-6.0) 4.7	(4.0-6.4)
The	results	were	expressed	by	the	data	of	median	(25%-	75%).
Table 1	Subjects	classified	for	4	groups	due	to	average	glucose	level.
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Figure 1 Correlation	between	average	glucose	and	HbA1c.	Both	
factors	revealed	significant	correlation	(p<0.01).
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Figure 2 Correlation	 of	 urinary	 C-peptide	 excretion	 between	
day 2 and 4. CR diet was provided on day 1 and 2, and 
LCD	was	provided	from	day	3	to	14.	Urinary	C-peptide	
excretion	was	measured	for	24	hours	during	the	formula	
diet which is CR or LCD.
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Comparison of average glucose and M value between CR and LCD. A) Average 
glucose	on	day	2	and	4	revealed	significant	correlation	(p<0.01)	and	glucose	level	
decreased	according	to	the	regression	curve	(y	=	0.5765x	+	36.36).	B) M value on day 
2	and	4	revealed	significant	correlation	(p<0.01)	and	M	value	decreased	according	
to	the	regression	curve	(y	=	0.2873x	-	8.3151).
Figure 4 Correlation	of	average	glucose	and	M	value	on	CR	and	LCD.	A) Average glucose and
M	value	on	day	2	revealed	significant	correlation	(p<0.01).	B) Similarly, both factors 
had	significant	correlation	(p<0.01).	Compared	with	both	figures,	average	glucose	
and M value on day 4 decreased apparently.
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Figure 5 The change of M value in each group from day 2 to day 4. A) Group 1 revealed almost 
same median value, and group 2 revealed decreased median values. B) Group 3 and 4 
revealed	decreased	median	levels	from	day	2	to	day	4.	Boxplot	shows	5	components,	
which	are	median.	25%	quartile,	75%	quartile,	maximum	and	minimum.	
Figure 6 The change of triglyceride level from day 2 to day 14. In response to LCD for 12 
days,	 triglyceride	 level	was	significantly	decreased	(p<0.05).	The	regression	curve	
(y=0.3738x+44.072)	reveled	the	degree	of	decreased	TG.
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Figure 7 Correlation	of	RLP-C	and	triglyceride	/	LDL-C	on	day	2.	A)	RLP	and	triglyceride	levels
revealed	significant	correlation	(p<0.01).	B)	RLP	and	LDL-C	levels	revealed	significant	
correlation	(p<0.05).
Figure 8 Correlation	of	RLP-C	and	biomarkers.	A)	Significant	correlation	was	shown	between	RLP-C
and	 atherogenic	 index	 which	 is	 calculated	 by	 T-C	 –HDL	 /	 HDL	 (p<0.05).	 B)	 Significant	
correlation	was	shown	between	RLP-C	and	TG/HDL	value	(p<0.01).
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Discussion
In	north	American	and	European	countries,	LCD	has	been	more	
prevalent	as	Bernstein,	Atkins	and	others	have	continued	clinical	
research	 for	years	 [1-6,22-25].	 In	 Japan,	author	and	colleagues	
have	 developed	 LCD,	 and	 investigated	 studies	 for	 metabolic	
syndrome	with	2699	cases,	T2DM,	elevated	ketone	bodies	and	
glucose	variability	as	M	value	[7-10,26].	
In	this	study,	we	adopted	super-LCD	including	12%	carbohydrate,	
which	 is	 equivalent	 to	 VLCKD.	Our	 formula	 diet	 contains	 1400	
kcal/day,	which	has	168	kcal	of	carbohydrate	(1400	kcal	×	0.12),	
and	42	g	of	 carbohydrate	per	day	 [7,9,19]	which	 is	one	of	 the	
very	low-carbohydrate	ketogenic	diet	(VLCKD)	by	the	definitions	
of	LCD	[5].	
Daily	glucose	profile	can	be	estimated	by	MAGE	and	M	(Morbus)	
values	 [11,12],	 and	 the	 latter	 would	 be	 more	 practical.	 There	
were	similar	results	on	7	times	or	20	times	of	sampling	per	day	
[11,13,21],	showing	similar	result	in	comparison	with	continuous	
glucose	monitoring	(CGM)	[27-30].	
Average	 blood	 glucose	 in	 4	 groups	 decreased,	 indicating	 the	
short	 effect	 of	 LCD	 only	 for	 2	 days	 from	 CR	 to	 LCD.	 M	 value	
also	 significantly	 decreased	 in	 group	 2,3	 and	 4.	 M	 value	 is	
characterized for its larger numerical change than that of glucose, 
and	for	better	evaluation	of	relieving	status.	On	contrast,	M	value	
in group 1 was not so changed from day 2 to 4, which seemed 
to	be	 the	 characteristic	point	of	M	value.	 If	 the	average	blood	
glucose	decrease	 from	100	mg/dl	 to	80	mg/dL,	M	value	would	
increase because M value becomes minimum level when blood 
glucose	is	100	mg/dL.	
For	 only	 2	 days of formular LCD, there were considerable 
decrease	 of	 average	 glucose,	 urinary	 C-peptide	 excretion	 and	
M	 value.	 Obtained	 linear	 regression	 curve	 would	 become	 the	
reference	data	for	this	area	of	research.	The	decrease	ratio	of	M	
value is larger than that of glucose, because M value represents 
both	average	glucose	and	MAGE.	
Recently,	 the	 research	 of	 LCD	 have	 focused	 to	 less	 influence	
to	 cardiovascular	 risk	 factors,	 and	 research	 the	 relationship	
between	glucose	and	lipids	metabolism	[31-33].	
Isolation	 of	 remnant-like	 particles	 (RLPs)	 was	 performed	 and	
investigated,	 which	 are	 thought	 to	 be	 atherogenic	 agent	 [15].	
RLP-C	was	 supposed	 to	 be	 an	 independent	 risk	 factor	 for	 CVD	
in	women,	and	provides	significantly	more	information	than	do	
triglycerides	[16,34].	After	that,	Epidemiologic	studies	have	shown	
associations	 between	 RLP	 concentrations	 and	 atherosclerosis,	
cardiovascular	 disease	 (CVD),	 and	 chronic	 heart	 disease	 (CHD)	
[17,35].	
Elevated	 RLP-C	 were	 observed	 in	 T2DM	 [16,34,36].	 Diabetes	
Atherosclerosis	 Intervention	 Study	 (DAIS)	 had	measured	 RLP-C	
and	 TG	 levels,	 which	were	 significantly	 higher	 in	 diabetic	 CAD	
group	than	non-diabetic	CAD	group	[37].	Furthermore,	The	AUCs	
of	 TG	or	 RLP-C	 showed	 a	 correlation	with	 the	AUCs	of	 plasma	
insulin,	 with	 the	 correlation	 with	 the	 insulin	 resistance	 index	
[37,38].	
In	metabolic	 syndrome,	 obesity	 and	 insulin	 resistance,	 ratio	of	
triglycerides	 to	high-density	 lipoprotein	 cholesterol	 (TG/HDL-C)	
would	be	high	[39].	By	the	data	from	1.35	million	US	individuals,	
median	TG/HDL-C	ratio	was	2.2,	and	increasing	TG/HDL-C	ratios	
would	accompany	increasing	levels	of	RLP-C,	non-HDL-C	and	LDL	
density,	 with	 the	 highest	 relative	 increase	 of	 RLP-C	 and	 LDL-C	
[39].	
In	our	study,	TG/HDL-C	ratio	was	1.73(1.08-2.85).	As	to	current	
research	protocol	with	lipid	investigation,	we	enrolled	the	patients	
whose	triglyceride	was	less	than	250	mg/dL,	because	extremely	
high	value	of	 triglyceride	would	not	be	adequate	 for	 statistical	
analyses.	For	future	study,	we	will	analyze	those	patients	in	the	
combined research of glucose and lipid metabolism. 
As	 to	 correlation	 of	 RLP-C	 with	 4	 biomarkers	 which	 are	 TG,	
LDL-C,	TC-HDL/HDL	and	TG/HDL,	the	linear	regression	curve	and	
coefficient	value	could	become	the	reference	for	the	research	of	
lipid metabolism. 
Different	 dietary	 approaches	 on	 glycemic	 control	 has	 been	
in	 research,	 including	 9	 kinds	 of	 diet,	 namely,	 control,	 low-
carbohydrate,	low-fat,	Mediterranean,	high-protein,	vegetarian,	
DASH,	Paleo,	low-glycemic	index/load	[40-42].	Our	current	study	
would	be	useful	 for	 selecting	applicable	method.	Furthermore,	
interrelationship	research	between	glucose	and	lipid	metabolism	
would	develop	for	decreasing	diabetic	complication	in	the	future.	
Conclusion
• By	LCD	nutritional	therapy,	average	glucose	and	M	value
had	 considerably	 decreased,	 suggesting	 the	 efficacy	 of
LCD	and	the	clinical	useful	marker	of	LCD	for	the	patients
with T2DM.
• Investigation	of	lipid	metabolism	showed	considerable	TG
decrease	for	LCD	and	the	significant	relationship	between
RLP-C	and	triglyceride,	LDL-C,	TC-HDL/HDL,	TG/HDL.
• Current study would become fundamental data for the
field	 of	 T2DM,	 LCD	 and	 research	 direction	 for	 glucose/
lipid metabolism in the future.
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